Key result
CYP2C:TG haplotype shows no association with CYP2C19-mediated omeprazole metabolism in Latin American populations.
Why the study?
Is the CYP2C:TG haplotype associated with CYP2C19-mediated omeprazole metabolism in admixed Latin American populations?
Observational
Yes
Is the CYP2C:TG haplotype associated with CYP2C19-mediated omeprazole metabolism in admixed Latin American populations?
The study does not support clinical implementation of CYP2C:TG haplotype testing for predicting CYP2C19 activity in admixed Latin American populations.
CYP2C:TG testing should not be implemented in admixed Latin American populations; leaves open need for ancestry-specific CYP2C19 markers.
In these admixed Latin American populations, the CYP2C:TG haplotype was not significantly associated with CYP2C19-mediated omeprazole metabolism. This finding does not support clinical implementation of CYP2C:TG haplotype testing for predicting CYP2C19 activity and underscores the need for further research on this haplotype and its potential role in CYP2C19 metabolism across diverse populations in the context of pharmacogenetics.
No takes yet. Share an insight, caveat, or question.
Cruz et al. (2026) conducted an observational in CYP2C19-mediated omeprazole metabolism. CYP2C:TG haplotype was evaluated on CYP2C19-mediated omeprazole metabolism. The CYP2C:TG haplotype was not significantly associated with CYP2C19-mediated omeprazole metabolism in admixed Latin American populations, not supporting its clinical implementation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: